Your AI-Trained Oncology Knowledge Connection!
Combinations of checkpoint inhibitors and VEGF TKIs, as well as dual checkpoint blockade, are affording patients with advanced hepatocellular carcinoma greater potential for disease control and deep, long-lasting responses, underscoring the need for biomarkers of response to combination regimens and single-agent TKIs, the latter of which still play a role for select populations.
Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.
Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.
Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.
Previous exposure to immune checkpoint inhibitors or osimertinib has been linked with poor outcomes in patients with non–small cell lung cancer who were receiving a subsequent atezolizumab-containing regimen.
Amit Singal, MD, discusses downstaging strategies for patients with hepatocellular carcinoma.
The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.
Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.
Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.
First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.
The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.
The frontline combination of nivolumab and ipilimumab plus 2 cycles of chemotherapy demonstrated an improvement in overall survival vs chemotherapy alone in patients with advanced non–small cell lung cancer regardless of tumor mutational burden status in the tissue or blood.
Dostarlimab demonstrated durable antitumor activity in patients with mismatch repair deficient and MMR proficient endometrial cancer, regardless of investigator assessment or blinded independent central review and immune-related RECIST or RECIST v1.1 criteria.
Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.
Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.
Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.
The combination of pembrolizumab and lenvatinib improved progression-free and overall survival, as well as response rates, compared with chemotherapy in patients with advanced endometrial cancer who received prior platinum-based chemotherapy, irrespective of mismatch repair status, according to phase 3 findings of the Study-309/KEYNOTE-775 trial.
Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.
Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.
Corey S. Cutler, MD, MPH, FRCPC, discusses the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.
Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.
The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.
Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams
Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.
The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.
Anjana Pillai, MD, discusses sequential treatment in hepatocellular carcinoma.
Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.
A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden
Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.
Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.
